Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

723 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Roche: positive CHMP opinion for Alecensa
CF
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
GL
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
BU
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
GL
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
BU
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
GL
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure
AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
GL
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
BU
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
GL
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
AQ
Roche: FDA approves allergy treatment
CF
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
GL
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
BU
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
BU
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
GL
Roche cancer immunotherapy receives new EU approval
AQ
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
GL
FDA grants priority review to omalizumab for food allergies
AQ
Roche - FDA grants priority review to Xolair for children and adults with food allergies based on positive National Institutes of Health phase III study results
AQ
Roche's Xolair Granted FDA Priority Review
DJ
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
GL
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
BU
New data for Roche s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
AQ
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
GL
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
AQ
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
GL
Roche's Inavolisib Breast Cancer Drug Gets Positive Results
DJ
Roche: positive data for Kadcyla in breast cancer
CF
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
GL
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
GL
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
BU
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
BU
Roche to advance novel obesity and diabetes treatments
AQ
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
GL
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
BU
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update
DJ
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
GL
CHMP recommends new immunotherapy delivery method
AQ
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
GL
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
GL
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BU
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
GL
Roche to gain rights to novel antibody for IBD
AQ
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
GL
No results for this search
  1. Stock Market
  2. Advanced search
  3. Levi Garraway
  4. News